MiR-23a-3p, overexpressed among sorafenib non-responders, targets ACSL4 directly and leads to sorafenib resistance, while miR-23a-3p inhibition restores ACSL4 expression and triggers ferroptosis in hepatocellular carcinoma treated with sorafenib[133]. Here, ACSL4 is linked to hepatocellular carcinoma.